CR20140076A - 4-(8-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo [4,5-c] quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio - Google Patents

4-(8-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo [4,5-c] quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio

Info

Publication number
CR20140076A
CR20140076A CR20140076A CR20140076A CR20140076A CR 20140076 A CR20140076 A CR 20140076A CR 20140076 A CR20140076 A CR 20140076A CR 20140076 A CR20140076 A CR 20140076A CR 20140076 A CR20140076 A CR 20140076A
Authority
CR
Costa Rica
Prior art keywords
metoxipropan
dimethylyzoxolol
bromodominium
tetrahidro
piran
Prior art date
Application number
CR20140076A
Other languages
English (en)
Spanish (es)
Inventor
Emmanuel Hubert Demont
Katherine Louise Jones
Robert J Watson
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of CR20140076A publication Critical patent/CR20140076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CR20140076A 2011-08-17 2014-02-17 4-(8-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo [4,5-c] quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio CR20140076A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1114103.3A GB201114103D0 (en) 2011-08-17 2011-08-17 Novel compounds

Publications (1)

Publication Number Publication Date
CR20140076A true CR20140076A (es) 2014-03-19

Family

ID=44764570

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140076A CR20140076A (es) 2011-08-17 2014-02-17 4-(8-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo [4,5-c] quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio

Country Status (38)

Country Link
US (4) US9067936B2 (show.php)
EP (2) EP3150601A1 (show.php)
JP (1) JP6059723B2 (show.php)
KR (1) KR20140064878A (show.php)
CN (1) CN103889984B (show.php)
AR (1) AR087545A1 (show.php)
AU (1) AU2012296914B2 (show.php)
BR (1) BR112014003681A8 (show.php)
CA (1) CA2843537A1 (show.php)
CL (1) CL2014000365A1 (show.php)
CO (1) CO6862151A2 (show.php)
CR (1) CR20140076A (show.php)
CY (1) CY1118370T1 (show.php)
DK (1) DK2744809T3 (show.php)
DO (1) DOP2014000031A (show.php)
EA (1) EA023374B1 (show.php)
ES (1) ES2609857T3 (show.php)
GB (1) GB201114103D0 (show.php)
HR (1) HRP20161674T1 (show.php)
HU (1) HUE030106T2 (show.php)
IL (1) IL230489A (show.php)
IN (1) IN2014CN00568A (show.php)
JO (1) JO3187B1 (show.php)
LT (1) LT2744809T (show.php)
ME (1) ME02589B (show.php)
MX (1) MX350597B (show.php)
MY (1) MY170729A (show.php)
PE (1) PE20141406A1 (show.php)
PH (1) PH12014500379A1 (show.php)
PL (1) PL2744809T3 (show.php)
PT (1) PT2744809T (show.php)
RS (1) RS55560B1 (show.php)
SI (1) SI2744809T1 (show.php)
SM (2) SMT201700005T1 (show.php)
TW (1) TWI558704B (show.php)
UA (1) UA110838C2 (show.php)
UY (1) UY34264A (show.php)
WO (1) WO2013024104A1 (show.php)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR084070A1 (es) 2010-12-02 2013-04-17 Constellation Pharmaceuticals Inc Inhibidores del bromodominio y usos de los mismos
US9249161B2 (en) 2010-12-02 2016-02-02 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
EP2705039B1 (en) 2011-05-04 2017-07-26 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
WO2012174487A2 (en) 2011-06-17 2012-12-20 Constellation Pharmaceuticals, Inc. Bromodomain inhibitors and uses thereof
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds
TWI602820B (zh) 2012-06-06 2017-10-21 星宿藥物公司 溴域抑制劑及其用途
US9624244B2 (en) 2012-06-06 2017-04-18 Constellation Pharmaceuticals, Inc. Benzo [B] isoxazoloazepine bromodomain inhibitors and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
CA2895905A1 (en) 2012-12-21 2014-06-26 Zenith Epigenetics Corp. Novel heterocyclic compounds as bromodomain inhibitors
AU2014249192B2 (en) 2013-03-11 2017-12-21 The Regents Of The University Of Michigan BET bromodomain inhibitors and therapeutic methods using the same
US8980879B2 (en) 2013-03-11 2015-03-17 Abbvie Inc. Bromodomain inhibitors
JP2016512524A (ja) 2013-03-11 2016-04-28 アッヴィ・インコーポレイテッド ブロモドメイン阻害剤
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
TWI530499B (zh) * 2013-03-28 2016-04-21 吉李德科學股份有限公司 作為溴結構域（ｂｒｏｍｏｄｏｍａｉｎ）抑制劑之苯並咪唑酮衍生物類
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
PL3010503T3 (pl) 2013-06-21 2020-08-24 Zenith Epigenetics Ltd. Nowe bicykliczne inhibitory bromodomen
EP3019502B1 (en) 2013-07-08 2017-05-17 Incyte Holdings Corporation Tricyclic heterocycles as bet protein inhibitors
EP3027604B1 (en) 2013-07-31 2019-02-20 Zenith Epigenetics Ltd. Novel quinazolinones as bromodomain inhibitors
WO2015049629A1 (en) * 2013-10-01 2015-04-09 Piramal Enterprises Limited Imidazoquinoline compounds as bromodomain inhibitors
US9399640B2 (en) 2013-11-26 2016-07-26 Incyte Corporation Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
WO2015081189A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
WO2015095492A1 (en) * 2013-12-19 2015-06-25 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
CA2940554A1 (en) 2014-02-28 2015-09-03 The Regents Of The University Of Michigan 9h-pyrimido[4,5-b]indoles and related analogs as bet bromodomain inhibitors
KR102702503B1 (ko) 2014-04-23 2024-09-05 인사이트 홀딩스 코포레이션 BET 단백질의 저해제로서의 1H-피롤로[2,3-c]피리딘-7(6H)-온 및 피라졸로[3,4-c]피리딘-7(6H)-온
LT3157928T (lt) 2014-06-20 2019-05-27 Constellation Pharmaceuticals, Inc. 2-((4s)-6-(4-chlorfenil)-1-metil-4h-benzo[c]iizoksazolo[4,5-e]azepin-4-il)acetamido kristalinės formos
WO2016044130A1 (en) 2014-09-15 2016-03-24 Incyte Corporation Tricyclic heterocycles for use as bet protein inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
CN107207474B (zh) 2014-12-11 2021-05-07 恒翼生物医药科技(上海)有限公司 被取代的杂环作为溴结构域抑制剂
US10231953B2 (en) 2014-12-17 2019-03-19 Zenith Epigenetics Ltd. Inhibitors of bromodomains
WO2016123709A1 (en) * 2015-02-03 2016-08-11 Trillium Therapeutics Inc. Fluorinated imidazo[4,5-c]quinoline derivatives as inhibitors of bromodomain containing proteins
US10307407B2 (en) 2015-02-27 2019-06-04 The Regents Of The University Of Michigan 9H-pyrimido [4,5-B] indoles as BET bromodomain inhibitors
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) * 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016186453A1 (en) * 2015-05-20 2016-11-24 Kainos Medicine, Inc. Quinoline derivatives as bromodomain inhibitors
WO2016196065A1 (en) 2015-05-29 2016-12-08 Genentech, Inc. Methods and compositions for assessing responsiveness of cancers to bet inhibitors
WO2016199943A1 (en) * 2015-06-11 2016-12-15 Takeda Pharmaceutical Company Limited Heterocyclic compounds
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
AU2016305513A1 (en) 2015-08-11 2018-03-08 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
JP6912039B2 (ja) 2015-08-12 2021-07-28 ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ 置換ベンゾイミダゾール、それらの調製及び医薬品としてのそれらの使用
US10501459B2 (en) 2015-10-21 2019-12-10 Neomed Institute Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
US20170121347A1 (en) 2015-10-29 2017-05-04 Incyte Corporation Amorphous solid form of a bet protein inhibitor
US10519151B2 (en) 2016-01-28 2019-12-31 Neomed Institute Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
CN109071562B (zh) 2016-02-15 2022-03-22 密执安大学评议会 作为bet溴结构域抑制剂的稠合1,4-氧氮杂䓬和相关类似物
SG11201808728QA (en) 2016-04-06 2018-11-29 Univ Michigan Regents Mdm2 protein degraders
CA3020281A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
UA123168C2 (uk) 2016-04-12 2021-02-24 Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган Деструктори білка вет
PH12021551886A1 (en) 2016-06-20 2023-07-17 Incyte Corp Crystalline solid forms of a bet inhibitor
EP3512855B1 (en) 2016-09-13 2022-07-27 The Regents of the University of Michigan Fused 1,4-oxazepines as bet protein degraders
US10975093B2 (en) 2016-09-13 2021-04-13 The Regents Of The University Of Michigan Fused 1,4-diazepines as BET protein degraders
WO2018144789A1 (en) 2017-02-03 2018-08-09 The Regents Of The University Of Michigan Fused 1,4-diazepines as bet bromodomain inhibitors
US11267822B2 (en) 2017-09-13 2022-03-08 The Regents Of The University Of Michigan BET bromodomain protein degraders with cleavable linkers
CN108033957A (zh) * 2018-01-09 2018-05-15 中国药科大学 一种喹啉类BET bromodomain抑制剂及其制备方法和用途
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
WO2022132049A1 (en) * 2020-12-17 2022-06-23 National University Of Singapore Treating cancers using bet inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
GB0211649D0 (en) 2002-05-21 2002-07-03 Novartis Ag Organic compounds
EP1590348A1 (en) 2002-12-20 2005-11-02 3M Innovative Properties Company Aryl / hetaryl substituted imidazoquinolines
ES2388434T3 (es) 2003-11-03 2012-10-15 Glaxo Group Limited Dispositivo de administración de fluido
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
AU2006216997A1 (en) 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
WO2007035935A1 (en) 2005-09-23 2007-03-29 Coley Pharmaceutical Group, Inc. METHOD FOR 1H-IMIDAZO[4,5-c]PYRIDINES AND ANALOGS THEREOF
CA2634017A1 (en) 2005-12-16 2007-07-05 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines, imidazonaphthyridines, and imidazopyridines, compositions, and methods
JP2008156311A (ja) 2006-12-26 2008-07-10 Institute Of Physical & Chemical Research Ｂｒｄ２ブロモドメイン結合剤
JP5478262B2 (ja) * 2007-12-28 2014-04-23 田辺三菱製薬株式会社 抗癌剤
HUE026967T2 (en) * 2009-11-05 2016-07-28 Glaxosmithkline Llc Benzodiazepine Bromodomain inhibitor
GB0919423D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
GB0919432D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Use
GB201106799D0 (en) * 2011-04-21 2011-06-01 Glaxosmithkline Llc Novel compounds
GB201114103D0 (en) 2011-08-17 2011-09-28 Glaxosmithkline Llc Novel compounds

Also Published As

Publication number Publication date
CY1118370T1 (el) 2017-06-28
CO6862151A2 (es) 2014-02-10
JP6059723B2 (ja) 2017-01-11
US9067936B2 (en) 2015-06-30
EP2744809B1 (en) 2016-10-12
IL230489A (en) 2016-07-31
SMT201700005T1 (it) 2017-03-08
JO3187B1 (ar) 2018-03-08
RS55560B1 (sr) 2017-05-31
LT2744809T (lt) 2016-12-27
AR087545A1 (es) 2014-04-03
AU2012296914B2 (en) 2016-03-03
ME02589B (me) 2017-06-20
SMT201700005B (it) 2017-03-08
TW201323424A (zh) 2013-06-16
EP3150601A1 (en) 2017-04-05
MX2014001834A (es) 2014-02-27
PH12014500379A1 (en) 2021-07-12
CN103889984A (zh) 2014-06-25
GB201114103D0 (en) 2011-09-28
PT2744809T (pt) 2017-01-06
US20150315184A1 (en) 2015-11-05
HRP20161674T1 (hr) 2017-01-27
US9610284B2 (en) 2017-04-04
CL2014000365A1 (es) 2014-07-11
NZ620263A (en) 2016-04-29
BR112014003681A2 (pt) 2017-03-01
BR112014003681A8 (pt) 2018-01-23
US9861627B2 (en) 2018-01-09
US20160317529A1 (en) 2016-11-03
JP2014521735A (ja) 2014-08-28
SI2744809T1 (sl) 2017-01-31
HUE030106T2 (en) 2017-04-28
IL230489A0 (en) 2014-03-31
CA2843537A1 (en) 2013-02-21
US20140171462A1 (en) 2014-06-19
UY34264A (es) 2013-04-05
KR20140064878A (ko) 2014-05-28
MX350597B (es) 2017-09-11
UA110838C2 (uk) 2016-02-25
EA201490200A1 (ru) 2014-07-30
IN2014CN00568A (show.php) 2015-04-03
DK2744809T3 (en) 2017-01-23
ES2609857T3 (es) 2017-04-24
DOP2014000031A (es) 2014-06-01
PL2744809T3 (pl) 2017-08-31
TWI558704B (zh) 2016-11-21
WO2013024104A1 (en) 2013-02-21
EP2744809A1 (en) 2014-06-25
US20170157113A1 (en) 2017-06-08
US9416130B2 (en) 2016-08-16
AU2012296914A1 (en) 2014-02-13
CN103889984B (zh) 2016-01-13
MY170729A (en) 2019-08-27
EA023374B1 (ru) 2016-05-31
PE20141406A1 (es) 2014-10-25

Similar Documents

Publication Publication Date Title
CR20140076A (es) 4-(8-metoxipropan-2-il)-2-(tetrahidro-2h-piran-4-il)-1h-imidazo [4,5-c] quinolin-7-il)-3,5-dimetilisoxazol y su uso como inhibidor de bromodominio
SG194469A1 (en) Tetrahydroquinoline derivatives useful as bromodomain inhibitors
GB201106750D0 (en) Novel compounds
UY34418A (es) Compuestos derivados de la piridopiracina, su preparación, composiciones que los contienen y su uso en terapia
IL239639A0 (en) A modified spiropyrido {1,2-a} pyrazine derivative and its medicinal use as an HIV integrase inhibitor
GT201200321A (es) Derivados de heteroaril imidazolona como inhibidores de jak
AP4017A (en) Substituted triazolopyridines and their use as ttk inhibitors
CR20140031A (es) Derivados de piridin-2(1h)-ona como inhibidores de jak
EA201400771A1 (ru) Новые производные азетидина, фармацевтические композиции и их применение
UA111744C2 (uk) ЗАМІЩЕНІ ПІРИДОПІРАЗИНИ ЯК ІНГІБІТОРИ Syk
CO7020907A2 (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmacéuticas y métodos de uso de los mismos
ITMI20121306A1 (it) "tavolino da lavoro magnetico"
CL2015001116A1 (es) Composición y uso de dimeros de alquil cetena hidrogenados.
PH12014502294A1 (en) Triazolo compounds as pde10 inhibitors
DK2868318T4 (da) Injicerbar formulering
BR112015012825A2 (pt) piridopirazinas substituídas como inibidores de syk
BR112015005562A2 (pt) compostos de aminoisoquinolina, suas composições e uso dos novos compostos como inibidores da proteína quinase.
BR112014000773A2 (pt) composições de nicotinamida e uso terapêutico das mesmas
CL2014001862A1 (es) Compuestos derivados de morofolinilo sustituido, útiles como inhibidores de mogat-2; composicion farmaceutica que los comprende; uso en el tratamiento de hipertrigliceridemia.
UY34829A (es) Nueva dosificación y formulación
BR112013023575A2 (pt) “derivado de octaidrotienoquinolina, composição farmacêutica compreendendo o derivado, e uso destes”
IL232712A (en) [1, 2, 4] Triazulophyridines and their use as phosphodiesterase inhibitors
PL2521715T3 (pl) Piperazyny jako środki przeciwmalaryczne
EP2789613A4 (en) 1,4-DIHYDRO-NAPHTHYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF AND ITS USE
BR112015003033A2 (pt) composto, composição farmacêutica e uso do composto